Community post

Paul Kim (Locus Biosciences, Inc.) and colleagues published a paper on the results of the first phase of their Phase 2 ELIMINATE clinical trial, where they used a CRISPR-Cas3-enhanced phage cocktail to treat uncomplicated urinary tract infections. They found a well-tolerated dosing strategy, reduced E. coli in urine, and will now move onto the next stage of the trial.